Inhibition of CDK-Mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells

Cell Cycle

Volumn 13, Issue 20, 2014, Pages 3191-3201

  Tarasewicz, Elizabeth ^a   Rivas, Lisbi ^a   Hamdan, Randala ^a   Dokic, Danijela ^a   Parimi, Vamsi ^a   Bernabe, Beatriz Penalver ^b   Thomas, Alexandra ^a   Shea, Lonnie D ^a,b   Jeruss, Jacqueline S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

CDK; Cyclin; Paclitaxel; Smad3; Triple negative breast cancer

Indexed keywords

CATENIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; GELATINASE A; PACLITAXEL; PROTEIN P15; PROTEIN P21; SMAD3 PROTEIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; SMAD3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MODEL; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; PACLITAXEL; PHOSPHORYLATION; SMAD3 PROTEIN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84912079534     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.950126     Document Type: Article

References (56)

1. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F,Middleton L,Hortobagyi GN, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037-44; PMID:16505422; http://dx.doi.org/10.1200/JCO.2005.02.6914
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; http://dx.doi.org/10.1056/NEJMra 1001389
3. Fadare O, Tavassoli FA. Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol 2008; 5:149-59; PMID:18212769; http://dx.doi.org/10.1038/ncponc1038
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
5. Velasco-Velazquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG. Examining the role of cyclin D1 in breast cancer. Future Oncol 2011; 7:753-65; PMID:21675838; http://dx.doi.org/10.2217/fon.11.56
6. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75; PMID:12432043; http://dx.doi.org/10.1056/NEJMoa021153
7. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113:685-700; PMID:12809600; http://dx.doi.org/10.1016/S0092-8674(03)00432-X
8. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 2003; 63:3783-90; PMID:12839974
9. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ,Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005; 65:7968-75; PMID:16140969
10. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430: 226-31; PMID:15241418; http://dx.doi.org/10.1038/nature02650
11. Cooley A, Zelivianski S, Jeruss JS. Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines. Cell Cycle 2010; 9:4900-7; PMID:21150326; http://dx.doi.org/10.4161/cc.9.24.14158
12. Zelivianski S, Cooley A, Kall R, Jeruss JS. Cyclindependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin d-overexpressing breast cancer cells. Mol Cancer Res 2010; 8:1375-87; PMID:20736297; http://dx.doi.org/10.1158/1541- 7786.MCR-09-0537
13. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, Liu F. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 2010; 285:1754-64; PMID:19920136; http://dx.doi.org/10.1074/jbc.M109.063826
14. Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841-6; PMID:17908977; http://dx.doi.org/10.1158/1078-0432.CCR-07-1218
15. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase Cancer Res 2006; 66:7661-7; PMID:16885367; http://dx.doi.org/10.1158/0008-5472.CAN-06-1098
16. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, LeopoldWR, Pryer NK, et al. Specific inhibition of cyclindependent kinase 46 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38; PMID:15542782
17. Hughes L,Malone C, Chumsri S, Burger AM,McDonnell S. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 2008; 25:549-57; PMID:18386134; http://dx.doi.org/10.1007/s10585-008-9169-z
18. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT, van der Burg B. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 1995; 6: 1151-61; PMID:8519692
19. Lehmann BD, Bauer JA, Chen X, SandersME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
20. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res 2004; 6: R215-31; PMID:15084245; http://dx.doi.org/10.1186/bcr778
21. Bellis AD, Penalver-Bernabe B, Weiss MS, Yarrington ME, Barbolina MV, Pannier AK, Jeruss JS, Broadbelt LJ, Shea LD. Cellular arrays for large-scale analysis of transcription factor activity. Biotechnol Bioeng 2011; 108:395-403; PMID:20812256; http://dx.doi.org/10.1002/bit.22916
22. Weiss MS, Penalver Bernabe B, Bellis AD, Broadbelt LJ, Jeruss JS, Shea LD. Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture. PLoS One 2010; 5:e14026; PMID:21103341; http://dx.doi.org/10.1371/journal.pone.0014026
23. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University; Baltimore, MD 2014; http://omim.org/
24. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, Ten Dijke P. The TGF-betaSmad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 2011; 128:657-66; PMID:20821046; http://dx.doi.org/10.1007/s10549-010-1147-x
25. Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, Seki T, Matsui H, Fujisawa J, Okazaki K. Reversible smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 2007; 67:5090-6; PMID:17545585; http://dx.doi.org/10.1158/0008-5472.CAN-06-4629
26. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M, Hanai J, Akiyama H, Abe M, Miyazono K, et al. Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 2009; 284:6109-15; PMID:19122240; http://dx.doi.org/10.1074/jbc.M804659200
27. Zuo Y, Wu Y, Chakraborty C. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells. J Cell Physiol 2012; 227:1399-407; PMID:21618528; http://dx.doi.org/10.1002/jcp.22853
28. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46:48-57; PMID:17596875; http://dx.doi.org/10.1002/hep.21672
29. Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, Furukawa F, Sekimoto G, Watanabe T, Uemura Y, Sakaida N, et al. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res 2005; 65:157-65; PMID:15665291
30. Matsuzaki K, Okazaki K. Transforming growth factor-beta during carcinogenesis: the shift from epithelial to mesenchymal signaling. J Gastroenterol 2006; 41:295-303; PMID:16741607; http://dx.doi.org/10.1007/s00535-006-1795-0
31. Siletz A, Schnabel M, Kniazeva E, Schumacher AJ, Shin S, Jeruss JS, Shea LD. Dynamic transcription factor networks in epithelial-mesenchymal transition in breast cancer models. PLoS One 2013; 8:e57180; PMID:23593114; http://dx.doi.org/10.1371/journal. pone.0057180
32. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19:156-72; PMID:19153598; http://dx.doi.org/10.1038/cr.2009.5
33. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4:657-65; PMID:12923528; http://dx.doi.org/10.1038/nrm1175
34. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008; 40:383-408; PMID:18061509; http://dx.doi.org/10.1016/j.biocel.2007.09.006
35. Nagaria TS, Williams JL, Leduc C, Squire JA, Greer PA, Sangrar W. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFRHER-2 and mutant RASRAF breast cancer model systems. Neoplasia 2013; 15:939-51; PMID:23908594
36. Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, Carpen O, Hirsimaki P. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2009; 2:140; PMID:19615042; http://dx.doi.org/10.1186/1756-0500-2-140
37. Voduc D, Nielsen TO, Cheang MC, Foulkes WD. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol 2008; 39:1431-7; PMID:18620730; http://dx.doi.org/10.1016/j.humpath.2008.03.004
38. Jahn SC, Law ME, Corsino PE, Rowe TC, Davis BJ, Law BK. Assembly, activation, and substrate specificity of cyclin D1Cdk2 complexes. Biochemistry 2013; PMID:23627734; http://dx.doi.org/10.1021/bi400047u
39. Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl) 2012; 6:159-71; PMID:23133315; http://dx.doi.org/10.4137/BCBCR.S8205
40. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5:1876-83; PMID:10430095
41. Mao J, Song B, Shi Y, Wang B, Fan S, Yu X, Tang J, Li L. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel. Int J Biochem Cell Biol 2013; 45:1064-73; PMID:23500524; http://dx.doi.org/10.1016/j.biocel.2013.02.022
42. Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL, Wang W. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer 2013; 109:1876-85; PMID:24008666; http://dx.doi.org/10.1038/bjc.2013.534
43. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG, Jr. Selective killing of transformed cells by cyclincyclindependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999; 96:4325-9; PMID:10200261; http://dx.doi.org/10.1073/pnas.96.8.4325
44. McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES. CDK46 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 2012; 11:2747-55; PMID:22751436; http://dx.doi.org/10.4161/cc.21127
45. Leontieva OV, Blagosklonny MV. CDK46-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle 2013; 12: 3063-9; PMID:23974099; http://dx.doi.org/10.4161/cc.26130
46. Leontieva OV, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ 2013; 20:1241-9; PMID:23852369; http://dx.doi.org/10.1038/cdd.2013.86
47. McMasters KM, Hunt KK. Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life. J Clin Oncol 1999; 17:441-4; PMID:10080583
48. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 2009; 133:633-42; PMID:19391665; http://dx.doi.org/10.1043/1543- 2165-133.4.633
49. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25:4414-22; PMID:17785706; http://dx.doi.org/10.1200/JCO. 2007.10.6823
50. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004; 100:1365-73; PMID:15042669; http://dx.doi.org/10.1002/cncr.20134
51. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005; 102:13909-14; PMID:16172383; http://dx.doi.org/10.1073/pnas. 0506517102
52. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, MundyGR, Sun LZ. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006; 66:6714-21; PMID:16818646; http://dx.doi.org/10.1158/0008-5472.CAN-05-3565
53. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31:229-34; PMID:3724177; http://dx.doi.org/10.1002/jso.2930310402
54. R Development Core Team 2005. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. Vienna, Austria, 2012
55. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:1-25 Article3; PMID:16646809
56. Wickham H. ggplot2. Elegant Graphics for Data Analysis. New York, NY: Springer Science C Business Media, LLC, 2009